Drugs / PR1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00270452 | Dec 2005 → Oct 2007 | myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00415857 | Dec 2006 → Sep 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00415857 ↗ |
| Action | Deplete | “The vaccines then activate the immune system to make specialized cells that search out and kill the MDS, AML and CML cells containing the two proteins.” NCT00270452 ↗ |
| Modality | Vaccine | “We describe the safety and immunogenicity of a combined vaccine of 2 leukemia-associated antigenic peptides, PR1 and WT1.” PMID 17875804 ↗ Sep 2007 |
| Route | Subcutaneous | “one subcutaneous dose each of PR1 and WT1 vaccines in Montanide adjuvant” PMID 17875804 ↗ Sep 2007 |